GET DAILY SIGNALSWhy Is Vaxcyte (PCVX) Stock Down -3.67% Today?
Key Takeaways
- PCVX shares fell roughly 3.7% to about $63.80, surrendering the prior session's gain.
- The primary driver was profit-taking and continued consolidation following the early-October surge on positive Phase 3 OPUS-1 data for VAX-31.
- A post-readout equity financing and a long gap before the next clinical catalysts added to the overhang.
- The decline appeared largely stock-specific rather than tied to a broad biotech sell-off.
- Traders are now watching third-quarter earnings in early November and the 2027 data readouts.
Opening Summary
Vaxcyte, Inc. (PCVX), a clinical-stage vaccine developer headquartered in San Carlos, California, saw its shares pull back sharply in Wednesday's session. The stock traded near $63.80, down about $2.43, or 3.67%, from Tuesday's closing price of $66.23. The decline reversed the prior session's roughly 4% advance and extended a broader consolidation that has followed the company's blockbuster clinical announcement earlier in October. Markets attributed the move primarily to profit-taking after a steep re-rating of the shares, rather than to any single new corporate announcement.
Vaxcyte is best known for VAX-31, an investigational 31-valent pneumococcal conjugate vaccine (PCV) being developed to prevent invasive pneumococcal disease and pneumonia. Its pipeline also includes VAX-24, a 24-valent PCV candidate, and earlier-stage programs targeting Group A Streptococcus and Shigella.
Profit-Taking After the OPUS-1 Surge
The most important backdrop for today's decline is the stock's extraordinary rally earlier this month. On October 5, Vaxcyte disclosed that VAX-31 had met all pre-specified primary immunogenicity endpoints in the pivotal Phase 3 OPUS-1 trial in adults aged 50 and older. Shares surged roughly 31% that session, briefly touching a 52-week high near $90, as the data positioned VAX-31 as a potential best-in-class competitor to PFE's Prevnar franchise and Merck's Capvaxive.
In the two weeks since, the stock has been digesting those gains. Even after today's decline, the shares remain well above their pre-announcement levels near $56, reflecting the magnitude of the re-rating. Analysts have characterized the recent weakness as a natural consolidation following a sharp, catalyst-driven move, with investors locking in profits ahead of what is now a relatively quiet news window.
Dilution Overhang From Post-Readout Financing
A secondary factor weighing on sentiment is the financing activity that followed the positive data. Vaxcyte completed a substantial equity offering in the wake of the OPUS-1 results, raising on the order of $1 billion to fund its late-stage development and commercial manufacturing build-out. While the raise strengthened the balance sheet, it also increased the share count and diluted existing holders, a common near-term headwind for biotech companies that finance immediately after a favorable catalyst.
This overhang has been cited by sell-side commentary as one reason the stock has struggled to hold its post-data highs, alongside a lengthy wait for the next meaningful clinical updates.
A Long Wait for the Next Catalysts
Investors are also grappling with the timeline ahead. Vaxcyte has signaled that topline safety, tolerability, and immunogenicity data from the infant Phase 2 program, as well as results from the OPUS-2 and OPUS-3 adult Phase 3 studies, are not expected until the first half of 2027. A U.S. Biologics License Application submission is planned for the first half of 2028.
With no near-term data releases, the stock has become more sensitive to broader sector flows and to competitive headlines, including progress in Pfizer's 25-valent infant program, which some analysts flag as a potential longer-term competitive risk.
Market Context and Trading Activity
Trading volume in PCVX has tapered from the multi-million-share spikes seen around the October 5 announcement, and Wednesday's turnover was running roughly in line with, or modestly below, the stock's average daily volume. The lighter activity suggests the move was driven more by position adjustments and profit-taking than by a wave of aggressive new selling.
Technically, the shares remain well above their 50-day and 200-day moving averages despite the pullback, and they continue to trade within a wide 52-week range of $39.87 to $90.75. The stock's decline did not coincide with a clear breakdown of major technical support levels.
What Comes Next for PCVX
Looking ahead, the next scheduled catalyst is Vaxcyte's third-quarter financial report, expected in early November, which may include an updated outlook on spending and the pace of clinical enrollment. Beyond that, investors will focus on the infant Phase 2 readout and the OPUS-2 and OPUS-3 results anticipated in the first half of 2027, followed by the planned regulatory submission in 2028.
Key risks include the execution of the adult and infant development programs, competitive dynamics with established pneumococcal vaccine franchises, and the substantial capital required to scale manufacturing ahead of a potential commercial launch. Wall Street's consensus remains broadly constructive on the name, though the extended timeline to the next data milestones leaves the shares exposed to further volatility in the interim.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots currently performing strongly under live market conditions. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to explore. Visit the page to discover which AI-driven strategies are gaining momentum in today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PCVX in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 05, 2026
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In 41 of the 44 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 30 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In 58 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 35 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
PCVX moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 225 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.412) is normal, around the industry mean (2.988). P/E Ratio (-8.287) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology